Department of Radiation Oncology, Far Eastern Memorial Hospital, Taipei, Taiwan.
BMC Cancer. 2011 Jan 27;11:37. doi: 10.1186/1471-2407-11-37.
The aim of this study was to assess the treatment results and toxicity profiles of helical tomotherapy (HT) for postoperative high-risk oral cavity cancer.
From December 6, 2006 through October 9, 2009, 19 postoperative high-risk oral cavity cancer patients were enrolled. All of the patients received HT with (84%) or without (16%) chemotherapy.
The median follow-up time was 17 months. The 2-year overall survival, disease-free survival, locoregional control, and distant metastasis-free rates were 94%, 84%, 92%, and 94%, respectively. The package of overall treatment time > 13 wk, the interval between surgery and radiation ≤ 6 wk, and the overall treatment time of radiation ≤ 7 wk was 21%, 84%, and 79%, respectively. The percentage of grade 3 mucositis, dermatitis, and leucopenia was 42%, 5% and 5%, respectively.
HT achieved encouraging clinical outcomes for postoperative high-risk oral cavity cancer patients with high compliance. A long-term follow-up study is needed to confirm these preliminary findings.
本研究旨在评估螺旋断层放疗（HT）治疗口腔癌术后高危患者的疗效和毒性。
自 2006 年 12 月 6 日至 2009 年 10 月 9 日，我们共纳入 19 例口腔癌术后高危患者。所有患者均接受 HT 治疗（84%）或未接受（16%）化疗。
中位随访时间为 17 个月。2 年总生存率、无病生存率、局部区域控制率和远处无转移生存率分别为 94%、84%、92%和 94%。总治疗时间>13 周、手术与放疗间隔≤6 周和放疗总治疗时间≤7 周的患者比例分别为 21%、84%和 79%。3 级黏膜炎、皮炎和白细胞减少的发生率分别为 42%、5%和 5%。
HT 为口腔癌术后高危患者提供了令人鼓舞的临床结果，且患者具有较高的依从性。需要进行长期随访研究来证实这些初步发现。
